ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Emergency Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,761Medicare Part D Prescriptions Filled, Including Refills
$602K Total Retail Price of All Prescriptions
380 Patients Receiving at Least One Drug in Part D
63%Patients 65 Years and Older
90% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
LISINOPRIL 447 326
AMLODIPINE BESYLATE 426 351
SIMVASTATIN 332 230
FUROSEMIDE 255 187
NIFEDIPINE ER 211 145
HYDROCHLOROTHIAZIDE 206 162
METOPROLOL TARTRATE 198 167
OMEPRAZOLE 153 127
DIOVAN 150 122
METFORMIN HCL 135 97
OXYCODONE-ACETAMINOPHEN 119 44 S2
ACETAMINOPHEN-CODEINE 112 81 S3
HYDRALAZINE HCL 110 91
DONEPEZIL HCL 107 107
ATORVASTATIN CALCIUM 107 76
GABAPENTIN 105 51
NEXIUM 104 46
COLCRYS 104 86
CRESTOR 103 67
PANTOPRAZOLE SODIUM 88 72
POTASSIUM CHLORIDE 87 68
CLOPIDOGREL 86 57
LANTUS 81 52
CLONIDINE HCL 75 48
NAPROXEN 73 42
CARVEDILOL 69 42
GLIPIZIDE 66 49
PLAVIX 66 52
BYSTOLIC 65 43
RANITIDINE HCL 64 52
ZOLPIDEM TARTRATE 64 21
ATENOLOL 64 58
PREDNISONE 63 41
LEVOTHYROXINE SODIUM 55 35
NAMENDA 55 55
PROAIR HFA 55 35
SPIRONOLACTONE 54 36
CYCLOBENZAPRINE HCL 54 24 R
ADVAIR DISKUS 54 24
KLOR-CON M20 52 46
LISINOPRIL-HYDROCHLOROTHIAZIDE 52 22
VENTOLIN HFA 52 31
LACTULOSE 51 41
LOSARTAN-HYDROCHLOROTHIAZIDE 51 34
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.